- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,390 | 21.06.24 17:35:41 | -0,740 | -0,84% | 0,000 | 0,000 | 87,920 | 88,130 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.053,165 | 21.06.24 20:23:05 | +8,775 | +0,84% | 1.052,690 | 1.053,540 | 1.038,440 | 1.044,390 |
